— Transformational precision gene delivery company launched out of Versant’s Ridgeline Discovery Engine – — Vector developing platform for precisely targeted delivery of high-capacity genetic payloads — BASEL, Switzerland–(BUSINESS WIRE)–Versant Ventures today announced the debut of Vector BioPharma AG, a biopharmaceutical company developing a precision gene delivery platform that is devoid of viral genes. Versant … [Read more…]
BEDFORD, Mass.–(BUSINESS WIRE)–$OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022: Pre-Recorded Corporate Presentation Date: Wednesday, August 17, 2022 … [Read more…]
Patient engagement leader expands commitment to driving digital health technology as pandemic continues BETHESDA, Md,–(BUSINESS WIRE)–#Adventist–Patients using a remote patient monitoring program developed by Get Well, a global leader in digital patient engagement, to monitor and report COVID-19 symptoms had lowered hospitalization rates, spent less time in the intensive care unit, and had shorter overall … [Read more…]
OB-GYN Practice in Florida Uses PatientPop Technology to Enhance Its Online Presence SANTA MONICA, Calif.–(BUSINESS WIRE)–PatientPop, a market leader in practice growth technology, today announced that its successful partnership with OB-GYN Dr. Alan B. Patterson has resulted in a significant increase in new patients and business outcomes. Dr. Patterson began leveraging PatientPop’s services in 2017 … [Read more…]
Achieved record net product revenue of $25.3M – a 15% increase from Q1 ’22, and a 34% increase from same period prior year on a pro forma basis Ended Q2 with $111.6M in cash, cash equivalents and short-term investments Reaffirms full-year total net product revenue of $105M-$120M; $50M in synergies by year-end, 2022 year-end cash … [Read more…]
-The company-sponsored Phase 1/2 study is evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas – BOSTON–(BUSINESS WIRE)–Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing … [Read more…]
ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive NHL, as of May 31, 2022 data-cut date ADI-001 received FDA Fast Track Designation Strong balance sheet with $304.3 million in cash and cash equivalents, as adjusted for anticipated proceeds from … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Oncology Drugs Market (2022-2027) by Drug Class, Indication, End-user, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering. The Global Oncology Drugs Market is estimated to be USD 156.49 Bn in 2022 and is expected to reach USD 224.35 Bn by 2027, growing … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Ophthalmic Drug Delivery System Market 2021-2031 by Product, Dosage Form, Disease, Setting, and Region: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering. The global ophthalmic drug delivery system market will reach $ 30,013.7 million by 2031, growing by 6.9% annually over 2021-2031, driven by the growing prevalence of … [Read more…]
DUBLIN–(BUSINESS WIRE)–The “Global Cancer Pain Market (2022-2027) by Type, Disease Indication, Application, and Geography, Competitive Analysis, Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering. The Global Cancer Pain Market is estimated to be USD 8.14 Bn in 2022 and is projected to reach USD 10.45 Bn by 2027, growing at … [Read more…]
